Qilian International Holding Group Limited Operating Income 2011-2026 | QLI

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Qilian International Holding Group Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.39 M	4.81 M	6.18 M	5.97 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
6.18 M	2.39 M	4.84 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Burford Capital Limited BUR	242 M	$ 4.73	0.42 %	$ 761 M	Britain
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Alnylam Pharmaceuticals ALNY	502 M	$ 333.39	-1.77 %	$ 43.7 B	USA
Can-Fite BioPharma Ltd. CANF	-9.95 M	$ 3.17	3.93 %	$ 5.22 M	Israel
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
AlloVir ALVR	-46.2 M	-	4.14 %	$ 49.1 M	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aligos Therapeutics ALGS	-88 M	$ 7.42	-15.1 %	$ 73.3 M	USA
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-9.95 M	-	-2.5 %	$ 5.88 M	USA
Amphastar Pharmaceuticals AMPH	140 M	$ 21.68	1.4 %	$ 1.01 B	USA
Cabaletta Bio CABA	-172 M	$ 3.4	4.29 %	$ 342 M	USA
CymaBay Therapeutics CBAY	-102 M	-	-	$ 3.45 B	USA
BioNTech SE BNTX	15.3 B	$ 99.47	1.08 %	$ 27.2 B	Germany
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
ContraFect Corporation CFRX	-64.6 M	-	-5.16 %	$ 5.39 M	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	23.5 M	-	-	$ 399 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-71.1 M	$ 4.24	2.17 %	$ 453 M	USA
Arcutis Biotherapeutics ARQT	-12.2 M	$ 24.58	-2.03 %	$ 3.13 B	USA
AIkido Pharma AIKI	-55.7 M	-	1.93 %	$ 17.4 M	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	-271 M	$ 1.49	0.68 %	$ 397 M	Britain
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-22.4 M	-	-16.75 %	$ 25.8 M	USA
Celldex Therapeutics CLDX	-287 M	$ 33.87	1.62 %	$ 2.25 B	USA
AVROBIO AVRO	10.2 M	-	1083.1 %	$ 745 M	USA
Clearside Biomedical CLSD	-24.8 M	-	-	$ 25.3 M	USA
bluebird bio BLUE	-244 M	-	-	$ 546 M	USA
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA